4-戊基苯甲醛肟 | 175136-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-戊基苯甲醛肟
• 英文名称: 4-pentylbenzaldehyde oxime
• 英文别名: N-[(4-pentylphenyl)methylidene]hydroxylamine
• CAS: 175136-45-5
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: RWRBIFAHYUXCHC-UHFFFAOYSA-N

物化性质

• 沸点：
  285.6±19.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

SDS

Name:	4-Pentylbenzaldehyde oxime 97% Material Safety Data Sheet
Synonym:
CAS:	175136-45-5

Section 1 - Chemical Product MSDS Name:4-Pentylbenzaldehyde oxime 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175136-45-5	4-Pentylbenzaldehyde oxime	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175136-45-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H17NO
Molecular Weight: 191

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175136-45-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Pentylbenzaldehyde oxime - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175136-45-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175136-45-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175136-45-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-戊基苯甲醛肟 在 chloro(1,5-cyclooctadiene)(pentamethylcyclopentadiene)ruthenium(II) 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.67h， 生成
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS
  [FR] AMINOALKYLAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROTÉASE ASPARTIQUE DU PALUDISME

  摘要：

  本发明涉及作为疟疾蛋白酶质体酶II抑制剂的新型氨基烷基唑类化合物。这些化合物可用作治疗疟疾感染的药物或药物成分。

  公开号：

  WO2017069601A1
• 作为产物：
  描述：

  对戊基溴苯 在 正丁基锂 、 盐酸羟胺 、 碳酸氢钠 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 水 为溶剂， 反应 17.0h， 生成 4-戊基苯甲醛肟
  参考文献：
  名称：

  基于唑的非拟肽血浆蛋白酶抑制剂

  摘要：

  抗药性疟原虫的传播促使人们寻找新的抗疟药。疟疾天冬氨酸蛋白酶——血浆蛋白酶 (Plms)——在疟原虫生命周期的多个阶段有差异表达，被认为是有吸引力的药物靶点。我们报告了新型唑类非肽模拟血浆蛋白酶抑制剂的开发，该抑制剂是通过对 Actelion 氨基哌嗪抑制剂中的酰胺部分进行生物等排取代而设计的。最好的基于三唑的抑制剂对 Plm II 表现出亚微摩尔的效力，这与母体 Actelion 化合物相当。新抑制剂可作为开发无耐药性抗疟药的起点，靶向非消化性 Plm IX 或 X，这对疟原虫生命周期至关重要。

  DOI：

  10.1002/ardp.201800151

文献信息

• Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators
  作者：Fangchao Bi、Di Song、Nan Zhang、Zhiyang Liu、Xinjie Gu、Chaoyu Hu、Xiaokang Cai、Henrietta Venter、Shutao Ma

  DOI：10.1016/j.ejmech.2018.09.053

  日期：2018.11

  becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their

  临床上重要的细菌病原体中的抗生素耐药性正成为对公共卫生的普遍威胁，因此迫切需要具有新颖作用机制的新型抗菌剂。利用计算对接方法和基于结构的优化策略，我们合理地设计和合成了针对细菌细胞分裂蛋白FtsZ的两个系列的含异恶唑-3-基和异恶唑-5-基的苯甲酰胺衍生物。评估它们对一组革兰氏阳性和阴性病原体的活性表明，具有异恶唑-5-基的化合物B14和B16对包括耐甲氧西林的金黄色葡萄球菌在内的各种测试菌株均显示出强大的抗菌活性。和耐青霉素的金黄色葡萄球菌。进一步的分子生物学研究和对接分析证明，该化合物可作为有效抑制剂，通过刺激机制改变FtsZ自聚合动力学，最终终止细胞分裂并导致细胞死亡。综上所述，这些结果可能暗示了开发新型靶向FtsZ的杀菌剂的有希望的化学型。
• Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus
  作者：Di Song、Fangchao Bi、Nan Zhang、Yinhui Qin、Xingbang Liu、Yuetai Teng、Shutao Ma

  DOI：10.1016/j.bmc.2020.115729

  日期：2020.11

  Hela cells. Finally, a detailed discussion of structure-activity relationships was conducted, referring to the docking results. It is worth noting that substituting a 4,5-dihydroisoxazole ring for the isoxazole ring not only broadened the antibacterial spectrum but also resulted in a significant increase in antibacterial activity against S. aureus strains. Taken together, these results suggest a promising

  具有临床意义的细菌病原体（例如耐甲氧西林的金黄色葡萄球菌（MRSA）和耐万古霉素的金黄色葡萄球菌（VRSA））对抗生素的耐药性正成为对公共卫生的普遍威胁，因此，具有新颖作用机制的新型抗菌剂正在广泛使用。紧急需求。作为开发抗菌剂的持续努力的一部分，我们合理地设计和合成了针对细菌细胞分裂蛋白FtsZ的两个系列的含4,5-二氢异恶唑-5基和4,5-二氢异恶唑-3-基的苯甲酰胺衍生物。 。评价它们对一组革兰氏阳性和阴性病原体的活性表明，化合物A16拥有4,5-二氢异恶唑-5-基的化合物对各种测试菌株（包括耐甲氧西林，耐青霉素和临床分离的金黄色葡萄球菌）表现出出色的抗菌活性（MIC，≤0.125–0.5μg/ mL）。此外，进一步的小鼠感染模型表明，A16可能在体内有效并且对Hela细胞无毒。最后，参考对接结果对结构-活动关系进行了详细的讨论。值得注意的是，用4,5-二氢异恶唑环代替异恶唑环不仅扩大
• [EN] SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS<br/>[FR] AMINOALKYLAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROTÉASE ASPARTIQUE DU PALUDISME
  申请人：LATVIAN INST ORGANIC SYNTHESIS

  公开号：WO2017069601A1

  公开（公告）日：2017-04-27

  The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.

  本发明涉及作为疟疾蛋白酶质体酶II抑制剂的新型氨基烷基唑类化合物。这些化合物可用作治疗疟疾感染的药物或药物成分。
• Azole-based non-peptidomimetic plasmepsin inhibitors
  作者：Linda Kinena、Gundars Leitis、Iveta Kanepe-Lapsa、Raitis Bobrovs、Kristaps Jaudzems、Vita Ozola、Edgars Suna、Aigars Jirgensons

  DOI：10.1002/ardp.201800151

  日期：2018.9

  The spread of drug‐resistant malaria parasites urges the search for new antimalarial drugs. Malarial aspartic proteases – plasmepsins (Plms) – are differentially expressed in multiple stages of the Plasmodium parasite's lifecycle and are considered as attractive drug targets. We report the development of novel azole‐based non‐peptidomimetic plasmepsin inhibitors that have been designed by bioisosteric

  抗药性疟原虫的传播促使人们寻找新的抗疟药。疟疾天冬氨酸蛋白酶——血浆蛋白酶 (Plms)——在疟原虫生命周期的多个阶段有差异表达，被认为是有吸引力的药物靶点。我们报告了新型唑类非肽模拟血浆蛋白酶抑制剂的开发，该抑制剂是通过对 Actelion 氨基哌嗪抑制剂中的酰胺部分进行生物等排取代而设计的。最好的基于三唑的抑制剂对 Plm II 表现出亚微摩尔的效力，这与母体 Actelion 化合物相当。新抑制剂可作为开发无耐药性抗疟药的起点，靶向非消化性 Plm IX 或 X，这对疟原虫生命周期至关重要。